Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/29/26
AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, MerckInvestors Business Daily • 09/29/26
Buy 5 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' September DiviDogsSeeking Alpha • 09/26/26
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple MyelomaBusiness Wire • 09/25/26
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?Zacks Investment Research • 09/24/26
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?The Motley Fool • 09/24/26
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout24/7 Wall Street • 09/23/26
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-TermZacks Investment Research • 09/21/26
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026Business Wire • 09/18/26
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 09/17/26
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two YearsBusiness Wire • 09/17/26
How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year?24/7 Wall Street • 09/12/26
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 09/10/26